Oxycodone Orifarm (Oxycodone Hydrochloride)

Oxycodone Hydrochloride, the active ingredient in Oxycodone Orifarm, is an opioid analgesic presented as a controlled‑release tablet for oral use. It is prescribed for managing moderate to severe pain in adult patients when other analgesics are insufficient.

GNH USA supplies Oxycodone Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxycodone Orifarm is an opioid that acts on the central nervous system to relieve pain associated with several conditions. - Cancer‑related pain: Provides sustained relief of moderate to severe malignant pain. - Post‑surgical pain: Controls acute pain following major surgical procedures. - Chronic non‑cancer pain: Alleviates persistent pain when other treatments have failed. - Traumatic injury pain: Reduces pain from severe musculoskeletal injuries. - Palliative care pain: Improves comfort in end‑of‑life care.

Oxycodone Orifarm may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Constipation: Reduced gastrointestinal motility leading to hard stools. - Nausea: Feeling of queasiness, sometimes with vomiting. - Drowsiness: Generalized sedation or fatigue. - Dizziness: Light‑headed sensation, especially when standing quickly. - Dry mouth: Reduced salivation causing oral discomfort. - Pruritus: Itchy skin without rash.

Serious or Rare Side Effects: - Respiratory depression: Markedly slowed breathing that can be fatal. - Severe hypotension: Dangerous drop in blood pressure. - Seizures: Uncontrolled convulsive episodes. - Allergic reactions: Rash, swelling, or anaphylaxis. - Dependence and withdrawal: Physical and psychological reliance with withdrawal symptoms on abrupt cessation. - Cardiac arrhythmias: Irregular heart rhythms that may require emergency care.

When prescribing Oxycodone Orifarm, clinicians should evaluate patient history and monitor for adverse outcomes. - Assess renal and hepatic function: Adjust dosing in patients with impairment. - Evaluate risk of addiction: Screen for substance‑use disorder before initiating therapy. - Avoid concurrent CNS depressants: Concomitant use with alcohol or benzodiazepines can increase sedation. - Monitor for respiratory depression: Observe breathing, especially after dose escalation. - Counsel on constipation management: Recommend dietary fiber, fluids, and laxatives as needed. - Store below 25°C: Keep in the original container, protect from moisture and direct sunlight.

Oxycodone Orifarm can interact with several medication classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines: Combined use markedly increases risk of respiratory depression and profound sedation. - CNS depressants: Other sedatives, including barbiturates and antihistamines, can potentiate central nervous system depression. - MAO‑inhibitors: May cause hypertensive crisis or serotonin syndrome when combined.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): Increase oxy‑hydro‑hydro­hyd    ");